Orchid Pharma reports Q3 FY26 standalone results: sales ₹207 crore, EBITDA ₹13 crore, negative quarterly PBT; 9M FY26 sales ₹574 crore with corresponding earnings weakness. Investor presentation released for Q3 ended Dec 31, 2025, and call set for Feb 12, 2026.